ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Developing MasterKey Therapies to Defeat Cancer Resistance
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
S-1MEF